Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 913 of 6351
-
New antibiotic could fight tough diabetic foot infections
Disease control Recruiting nowThis is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Phase 3 • Sponsor: MicuRx • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC
-
Could a simple injection replace an IV for MS treatment?
Disease control CompletedThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy shows promise for rare lung cancer
Disease control CompletedThe SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B) before surgery as well as the safety and efficacy …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo shows promise for tough bladder cancer
Disease control Recruiting nowThis study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it sta…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New immunotherapy cocktails aim to outsmart resistant ovarian cancer
Disease control Recruiting nowThis study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New shot aims to save hearts after major attack
Disease control CompletedTo assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
Phase 3 • Sponsor: Faraday Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC
-
New hope for relapsed lung cancer: drug cocktail trial launches
Disease control Recruiting nowThis is a randomized, non-comparative, phase II study investigating whether: 1) the addition of durvalumab to investigator's choice second line chemotherapy prolongs survival versus investigator's choice second line chemotherapy in NSCLC patients with locally advanced disease pro…
Phase 2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can exercise rewind the aging clock? a new trial investigates
Knowledge-focused CompletedThis study investigated the effects of a structured 6-month high-intensity interval training (HIIT) program on blood DNA methylation-based measures of biological ageing, physical fitness, cardiovascular function, body composition, metabolic health, and the gut microbiome in adult…
Sponsor: Hungarian University of Sports Science • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Drug duo may unlock kidney transplants for 'impossible' patients
Disease control CompletedThis proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study aims to speed up stroke diagnosis with a simple spit or blood test
Diagnosis Recruiting nowIn adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection…
Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Ultrasound may predict Stroke-Causing plaques
Knowledge-focused CompletedObjective: To explore the association between spatio-temporal blood flow velocities (peak systole and end-diastole at prior-stenosis, at maximum stenosis, and post-stenosis) and carotid plaque vulnerability defined by histology staining. Secondary, to assess the association betwe…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
CT-Guided heart exams could cut radiation and time
Disease control CompletedCoronary computed tomography angiography (CCTA) is a non-invasive method for visualization of the coronary arteries. The anatomical information obtained by CCTA, however, is rarely integrated into a subsequent coronary intervention. The CT-FOCI trial aims to evaluate, in a random…
Sponsor: Aarhus University Hospital Skejby • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Brain surgery for Parkinson's: can we foresee the confusion that follows?
Knowledge-focused CompletedParkinson's disease (PD) is the second most common neurodegenerative disorder, with a rising incidence due to global aging. Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is a core therapeutic modality for motor symptoms in patients with moderate-to-advanced PD. Ho…
Sponsor: Beijing Tiantan Hospital • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
New asthma drug cuts severe attacks in Hard-to-Treat patients
Disease control CompletedTo asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Phase 4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New heart procedure could ease dual burden of heart failure and AF
Disease control Recruiting nowThe PACE-FIB trial is a multicentre, randomised, open-label clinical trial. Patients older than 18 years, with permanent AF, LVEF\>40%, average resting heart rate ≤ 110 beats per minute (bpm), at least one hospitalisation due to HF in the previous year and basal NT-proBNP level\>…
Sponsor: Daniel Rodríguez Muñoz • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
Glowing dye could help surgeons avoid cutting nerves
Diagnosis CompletedThis protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies to evaluate bevonescein.
Phase 3 • Sponsor: Alume Biosciences, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
New drug aims to help mitochondrial disease patients walk farther
Disease control CompletedSPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mu…
Phase 3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically)…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThe purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning ch…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New heart valve fix could spare patients from Open-Heart surgery
Disease control Recruiting nowThe objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom trans…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC